SFSusana Fernandes

Susana Fernandes

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Susana Fernandes has a total of 385 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The Importance of Familial Co‐segregation in the Classification of a Novel PKD1 Variant Associated With Autosomal Dominant Polycystic Kidney Disease

    by Alice Porto Vasconcelos, Liliana Rocha, Susana Fernandes, João Paulo Oliveira

    Autosomal dominant polycystic kidney disease (ADPKD) is a highly penetrant and clinically recognizable disorder, characterized by the presence of multiple bilateral kidney cysts. Variants in the PKD1 or PKD2 genes cause approximately 90% of cases, with the remaining 10% unresolved or caused by variants in other loci. This study demonstrates the utility of segregation studies for classifying genetic variants, as applied to a family with severe ADPKD and a novel PKD1 missense variant. A large family with multiple ADPKD patients is described. Genetic testing was performed using Sanger sequencing ( PKD1 and PKD2 ) or NGS panel ( PKD1 , PKD2, and PKHD1 genes). CNV were excluded using MLPA ( PKD1 , PKD2, and PKHD1 genes). Variants were classified using the 2015 ACMG–AMP guidelines, and the full likelihood Bayes factor (FLB) was computed with the “segregatr” R‐package (Version 0.3.0). The index patient and 13 family members across three generations had ultrasonographic confirmation of typical and progressive ADPKD. Preimplantation genetic testing (PGT) was requested, requiring molecular confirmation. The heterozygous PKD1 VUS c.8999G>C p.(Arg3000Pro) was identified in four affected patients and excluded in one unaffected patient. The FLB is 96.8, which, according to Jarvik and Browning's criteria, reclassified the variant as likely pathogenic. This classification aligned with ClinGen's 2024 recommendations and justified the PGT request. This family is clinically suggestive of PKD1 ‐related ADPKD and shares one VUS in PKD1 . FLB calculation enabled a rapid reclassification of the variant, demonstrating the value of segregation studies and accurate clinical phenotyping in genetic variant annotation.

  • Clinical and Genetic Epidemiology of Autosomal Dominant Polycystic Kidney Disease among Patients Incident on First Kidney Replacement Therapy between 1990 and 2023, in a Major Hospital in the Northwest of Portugal

    by Alexandra Silva, Pedro Lisboa Gonçalves, Liliana Capela, Liliana Rocha, Isabel Tavares, Susana Fernandes, João Paulo Oliveira

    Introduction: Autosomal dominant polycystic kidney disease (ADPKD) is the most common monogenic kidney disease, accounting for 5–10% of incident patients requiring kidney replacement therapy (KRT). Although most cases result from pathogenic variants in PKD1 (≈75%) or PKD2 (≈15%), clinical experience at a major academic hospital in Porto (ULSSJ) suggested a higher regional prevalence of ADPKD-PKD2, particularly involving the truncating variant PKD2 p.(Gln61*). This study aimed to characterize the clinical and genetic epidemiology of ADPKD in patients initiating KRT at ULSSJ, compare ADPKD-PKD1 with ADPKD-PKD2, and contrast local and national ADPKD prevalence among incident KRT patients. Methods: Nephrology reports for KRT initiation (NR-KRT) issued at ULSSJ from 1990 to 2023 were reviewed to identify ADPKD cases and extract demographic and clinical data. Genotypes were obtained from the Genetics Laboratory, Faculty of Medicine, University of Porto, or inferred through pedigree analysis. Next-generation sequencing was the first-tier genotyping test, with Sanger sequencing and multiplex ligation-dependent probe amplification for unresolved cases. National prevalence figures for ADPKD among incident KRT were retrieved from the Portuguese Society of Nephrology registry. Results: Among 6791 NR-KRT reviewed, 426 ADPKD patients were identified. Genotyping information was available for 168 individuals (39.4%), including 101 (60.1%) with inferred genotypes. Among genetically resolved cases, 70.2% had ADPKD-PKD1 and 29.8% had ADPKD-PKD2. Mean age at KRT initiation was 54.5 years in ADPKD-PKD1 and 66.9 years in ADPKD-PKD2. The PKD2 p.(Gln61*) variant was present in 39 patients (23.2%). Between 2010 and 2023, ADPKD prevalence among incident KRT patients was 7.48% at ULSSJ versus 5.19% nationwide (p < 0.0001). Conclusion: The prevalence of ADPKD among incident KRT patients at ULSSJ exceeded national rates. ADPKD-PKD1 was associated with earlier kidney failure compared to ADPKD-PKD2. The PKD2 p.(Gln61*) variant was the most frequent pathogenic allele identified. Given historical patterns of Portuguese emigration, these findings likely have broader international clinical relevance.

  • Open Access

    Genome Sequencing of Undiagnosed European Patients Suspected of Hereditary Cancer: Diagnostic Yield and Identification of Candidate Causative Variants

    by Nelson Martins, Mariona Terradas, José Garcia-Pelaez, Anna K. Sommer, German Demidov, Leslie Matalonga, Mireia Ramos-Muntada, Iris B.A.W. Te Paske, Isabel Spier, Arjen Mensenkamp, et al.

    PURPOSE: Hereditary cancers represent 5%-10% of all cancers, typically characterized by familial aggregation, early onset, and/or multiple primary tumors. Isolated cases with extreme early-onset or multiple unrelated cancers are rare and frequently underdiagnosed. This study aimed to improve genetic diagnostic yield in unresolved patients with strong clinical suspicion of hereditary cancer. Inclusion criteria were (1) ≥4 primary tumors in different organs (or ≥3 if two are rare), (2) adult-type cancers at ≤25 years, or (3) profuse gastrointestinal adenomatous polyposis before age 50 years or profuse polyposis of unknown type before age 30 years. METHODS: Germline DNA from 98 patients selected through ERN-GENTURIS underwent short-read whole-genome sequencing (WGS). Ninety had received negative results from standard genetic testing, whereas eight had not been tested. Variant analysis was performed using the RD-Connect GPAP and Solve-RD frameworks. RESULTS: Pathogenic or likely pathogenic variants in phenotype-related high-penetrance genes were found in 6% of patients, including APC and TP53 mosaicisms and germline variants in TP53 , BAP1 , BARD1 , and MBD4 (homozygous). Three patients carried pathogenic variants in hereditary cancer genes unrelated to their phenotype, and a heterozygous ERCC3 pathogenic variant was detected in a young patient with breast cancer. Suggestive variants of uncertain significance were identified, including a chromosome 3 inversion affecting VHL and MLH1 in a patient with renal and gastric cancers. Potentially regulatory noncoding variants in phenotype-associated genes were observed in 15% of patients (22 variants). CONCLUSION: Comprehensive resequencing of patients suspected of hereditary cancer increased the diagnostic yield by 6%. Detected pathogenic variants involved phenotype-related genes not previously analyzed or missed because of mosaicism. WGS further enables identification of novel gene associations and structural, deep intronic, or regulatory variants.


  • Whole-Exome Sequencing Targeting a Gene Panel for Sensorineural Hearing Loss: The First Portuguese Cohort Study

    by Cláudia Sousa Reis, Sofia Quental, Susana Fernandes, Sérgio Castedo, Carla Pinto Moura

    Next-generation sequencing (NGS) technologies revolutionized the molecular diagnosis of sensorineural hearing loss (SNHL) and are now a standard of care. In this study, 71 Portuguese probands with hereditary SNHL were assessed by whole-exome sequencing (WES) targeting a panel of 158 genes related to SNHL, aiming to evaluate the diagnostic yield of this methodological approach and to report the spectrum of variants. Patients with either nonsyndromic or syndromic SNHL were included. Also, patients were previously screened for variants in the GJB2 gene and for duplications/deletions in the GJB6 gene. Causative variants in 11 different genes were identified in 15 (21.1%) out of 71 probands, 5 of which had associated syndromes. In 6 other patients (8.5%), presumptive causative variants were identified in MYO15A, TMIE, TBC1D24, SPMX, GJB3, PCDH15, and CDH23 genes, uncovering a potential case of digenic Usher syndrome. The study was inconclusive in 20 probands (28.2%), in 19 due to lack of segregation analysis and in one due to uncertain phenotype-genotype matching. In the remaining 30 patients (42.3%) no potentially causative variants were identified. The diagnostic yield did not significantly vary according to the age of hearing-impairment onset. As the first study on the application of NGS technologies in SNHL based on a Portuguese cohort, our results may contribute to characterize the spectrum of variants related to SNHL in the Portuguese population. Additionally, the present study provides new insights into the contribution of MYO3A, TECTA, EDNRB, TBC1D24, and GJB3 genes to SNHL. For the significant number of undiagnosed patients, reanalysis of WES data – either for a broader gene panel or in a non-targeted approach – may be considered.


  • Open Access

    The CDH1 c.1901C>T Variant: A Founder Variant in the Portuguese Population with Severe Impact in mRNA Splicing

    by Rita Barbosa-Matos, Rafaela Leal Silva, Luzia Garrido, Ana Cerqueira Aguiar, José Garcia-Pelaez, Ana André, Susana Seixas, Sónia Passos Sousa, Luísa Ferro, Lúcia Vilarinho, et al.

    Hereditary diffuse gastric cancer (HDGC) caused by CDH1 variants predisposes to early-onset diffuse gastric (DGC) and lobular breast cancer (LBC). In Northern Portugal, the unusually high number of HDGC cases in unrelated families carrying the c.1901C>T variant (formerly known as p.A634V) suggested this as a CDH1-founder variant. We aimed to demonstrate that c.1901C>T is a bona fide truncating variant inducing cryptic splicing, to calculate the timing of a potential founder effect, and to characterize tumour spectrum and age of onset in carrying families. The impact in splicing was proven by using carriers’ RNA for PCR-cloning sequencing and allelic expression imbalance analysis with SNaPshot. Carriers and noncarriers were haplotyped for 12 polymorphic markers, and the decay of haplotype sharing (DHS) method was used to estimate the time to the most common ancestor of c.1901C>T. Clinical information from 58 carriers was collected and analysed. We validated the cryptic splice site within CDH1-exon 12, which was preferred over the canonical one in 100% of sequenced clones. Cryptic splicing induced an out-of-frame 37bp deletion in exon 12, premature truncation (p.Ala634ProfsTer7), and consequently RNA mediated decay. The haplotypes carrying the c.1901C>T variant were found to share a common ancestral estimated at 490 years (95% Confidence Interval 445–10,900). Among 58 carriers (27 males (M)–31 females (F); 13–83 years), DGC occurred in 11 (18.9%; 4M–7F; average age 33 ± 12) and LBC in 6 females (19.4%; average age 50 ± 8). Herein, we demonstrated that the c.1901C>T variant is a loss-of-function splice-site variant that underlies the first CDH1-founder effect in Portugal. Knowledge on this founder effect will drive genetic testing of this specific variant in HDGC families in this geographical region and allow intrafamilial penetrance analysis and better estimation of variant-associated tumour risks, disease age of onset, and spectrum.


  • Open Access

    GJB2: Frequency of the Less Common Variants in a Sample of the Portuguese Population

    by Cláudia Sousa Reis, Ana Cristina Santos, Henrique Barros, Susana Fernandes, Carla Pinto Moura

    Introduction: Sequence variants in the GJB2 gene account for up to 50% of cases of non-syndromic sensorineural hearing loss in the Caucasian population. In this study, we report the frequency of the less common variants of the GJB2 gene in a Portuguese sample and compare these frequencies with those of a group of hearing-impaired patients. Material and Methods: In order to select the less common GJB2 variants, 147 hearing-impaired patients followed in Centro Hospitalar Universitário de São João were evaluated. Afterwards, the presence of those variants was tested in 360 individuals from Generation 21. Results: The patient assessment enabled the selection of 11 GJB2 variants. Of those, 10 were investigated in Generation 21 participants, with only four being detected, in heterozygosity: p.Phe83Leu, p.Arg127His, p.Val153Ile and p.Asn206Ser, with the allelic frequencies (95% confidence interval) of 0.14% (0.01% - 0.87%), 0.28% (0.01% - 1.08%), 0.97% (0.43% - 2.04%) and 0.14% (0.01% - 0.88%), respectively. Two variants, p.Val37Ile and p.Val95Met, were more frequent in the patients’ group with statistical significance. Discussion: Our results allow for the p.Arg127His and p.Val153Ile variants to comply with polymorphism criteria and support the pathogenicity of p.Val37Ile and p.Val95Met variants. Moreover, two cases of moderate hearing loss were explained by the p.Val37Ile/p. Asn206Ser genotype, substantiating both the pathogenicity of such variants and the hypothesis that compound heterozygosity with p.Ans206Ser is associated with mild-moderate genotypes. Conclusion: Understanding the role of the variants is essential in order to provide genetic counselling to patients and their families. We explored a set of uncommon GJB2 variants that comprised 12% of the hearing-impaired patients in this study, supporting the relevance of their description.

  • Open Access

    Clinical and molecular characterization of Y microdeletions and X‐linked CNV67 implications in male fertility: a 20‐year experience

    by A. Pinho, A. Barros, S. Fernandes

    Background: Approximately 15% of couples worldwide are affected with infertility, attributed to a male co‐factor in about half of the cases. Y chromosome microdeletions are the second most common genetic cause for male infertility, with a global prevalence of 2–10% in infertile men. Recently, CNV67, localized in X chromosome, has emerged as potential contributor to male infertility, with a described frequency of 1.1% in the oligo/azoospermic men.Objectives: To investigate the prevalence of Y‐linked CNVs in a cohort of Portuguese infertile men and correlate the patients’ phenotypes with a genetic alteration; to investigate the CNV67 deletion in a subset of patients and corroborate the role of this CNV in male infertility.Materials and methods: We retrospectively analysed a database of 4000 Portuguese infertile men for karyotype anomalies and Y microdeletions and selected a cohort of 400 for CNV67 screening analysis by quantitative PCR or single PCR plus/minus.Results: Karyotype anomalies were present in 263 patients (6.6%), with Klinefelter syndrome representing the most frequent karyotype anomaly (2.8%). Among the 4000 patients, the prevalence of Yq microdeletions was 4.6%. Ninety microdeletions (10.0%) were found in the azoospermic group, 44 deletions (4.5%) in the severe oligozoospermic group, 1 AZFc partial deletion (0.3%) in the mild–moderate oligozoospermic group and 2 partial AZFc deletions (0.4%) in the normozoospermic group. Complete AZFc deletions represented 56.8% of the Yq microdeletions. The CNV67 deletion frequency was 1.2% in the studied sample.Conclusions: This study presents one of the largest samples of infertile men worldwide with the main purpose of correlating the Yq microdeletions with sperm count. Our findings are supported by previous reviews with large data and provide a reliable estimation of the prevalence of these anomalies in a Portuguese population. CNV67 was exclusively deleted in patients with spermatogenic impairment, showing a consistent genotype–phenotype correlation and a significant prevalence.


  • Acromegaly and acromegaloidism, two rare insulin-resistance conditions in one patient: reason for GH-IGF-1 discrepancy?

    by Paula Freitas, Vanessa Guerreiro, Irene Bernardes, Josue Pereira, Roberto Pestana Silva, Susana Fernandes, David Carvalho

    Introduction: Lipodystrophies are a group of genetic or acquired diseases characterized by abnormal adipose tissue deposition, frequently associated with insulin resistance, diabetes mellitus, dyslipidaemia, hypertension and hepatic steatosis. Congenital generalized lipodystrophy (LCG) is a well-defined syndrome with autosomal recessive heredity, prevalence <1:10million, with about 400 cases being described. Extreme shortage of subcutaneous adipose tissue, muscle hypertrophy and other adipose tissues, confer an acromegaloid-like appearance in patients with LCG, however no case of SBS and acromegaly has been reported. Clinical case: 63-year-old man appealed to endocrinology clinic for suspected lipodystrophy. He had lipoatrophy of upper and lower limbs, muscular prominence, acromegaly facies with thick lips, widening of the wings of the nose, creased nasolabial grooves, dental diastema, prominence of supraciliary arches, large hands and feet and soft tissue tumescence. No acanthosis nigricans. None of the parents had changes in body composition or diabetes. His 59-year-old sister has similar phenotype. He had dyslipidaemia (total-cholesterol: 192 mg/dl, HDL:31 mg/dl, LDL1: 41 mg/dl, triglycerides: 440 mg/dl); increased IGF-1: 379–481–410 ng/mL (NL<269); HOMA-IR: 11.93, A1c:6.4%. 1st OGTT: Impaired glucose tolerance (0 h:101; 2 h:186 mg/dl) and GH-0h:1.5; nadir:0.92 ng/ml; second OGTT 10 months after-diabetes (glucose 0 h:120; 2 h: 204 mg/dl) and GH-0h:0.98; nadir: 0.64 ng/ml). Thyroid function, gonadal, metabolism calcium phosphate, prolactin, ACTH, and cortisol are normal. There was a ratio of fat mass trunk/limbs to 1.02 by densitometry and without osteoporosis. Colonoscopy and upper digestive endoscopy were normal. A 17 cm hepatomegaly with mild steatosis was detected on abdominal ultrasound. Left ventricular hypertrophy was observed in the ECG. In the pituitary MRI was found an area of hypocaptation contrast product with rounded aspect in right half of pituitary gland, passing midline to opposite side and prophesying to sphenoid sinus in relation to the pituitary adenoma. No deviation of the pituitary stalk. Subjected to transphenoidal pituitary surgery pathological evaluation showed pituitary adenoma, with extensive expression of GH and ACTH and rare expression of FSH and PRL. Genetic study revealed a intron3/exon3 deletion of the AGPAT2 gene in homozygosity. A GH/IGF-1 discrepancy, IGF-1 increased with normal GH variant was present. The role of insulin resistance or hepatic steatosis isn’t clear and could disturb the diagnosis. Conclusion: GCL is a rare disease that occurs with acromegaly; however, no case of genetic lipodystrophy associated with acromegaly has been described in the literature.

  • Novel Missense LCAT Gene Mutation Associated with an Atypical Phenotype of Familial LCAT Deficiency in Two Portuguese Brothers

    by I. Castro-Ferreira, Rute Carmo, Sérgio Estrela Silva, Otília Corrêa, Susana Fernandes, Susana Sampaio, Rodrigues-Pereira Pedro, Augusta Praça, João Paulo Oliveira

    Familial lecithin-cholesterol acyltransferase deficiency (FLD) is a rare recessive disorder of cholesterol metabolism, caused by loss-of-function mutations in the human LCAT gene, leading to alterations in the lipid/lipoprotein profile, with extremely low HDL levels. The classical FLD phenotype is characterized by diffuse corneal opacification, haemolytic anaemia and proteinuric chronic kidney disease (CKD); an incomplete form, only affecting the corneas, has been reported in a few families worldwide. We describe an intermediate phenotype of LCAT deficiency, with CKD preceding the development of corneal clouding, in two Portuguese brothers apparently homozygous for a novel missense LCAT gene mutation. The atypical phenotype, the diagnosis of membranous nephropathy in the proband’s native kidney biopsy, the late-onset and delayed recognition of the corneal opacification, the co-segregation with Gilbert syndrome and the late recurrence of the primary disease in kidney allograft all contributed to obscure the diagnosis of an LCAT deficiency syndrome for many years. A major teaching point is that on standard light microscopy examination the kidney biopsies of patients with LCAT deficiency with residual enzyme activity may not show significant vacuolization and may be misdiagnosed as membranous nephropathy. The cases of these two patients also illustrate the importance of performing detailed physical examination in young adults presenting with proteinuric CKD, as the most important clue to the diagnosis of FLD is in the eyes.


  • Open Access

    DNA methylation imprinting errors in spermatogenic cells from maturation arrest azoospermic patients

    by P. I. Marques, S. Fernandes, F. Carvalho, A. Barros, M. Sousa, C. J. Marques

    Summary: Imprinting errors have been described in spermatozoa from infertile patients with oligozoospermia and azoospermia. However, little is known about methylation of imprinted genes in other spermatogenic cells from azoospermic patients. Therefore, we aimed to evaluate the methylation status of single CpGs located in the differentially methylated regions (DMRs) of two imprinted genes, one paternally (H19) and one maternally (MEST) methylated, in primary spermatocytes of azoospermic patients presenting complete (MAc, n = 7) and incomplete (MAi, n = 8) maturation arrest, as well as in other spermatogenic cells from MAi patients that presented focus of complete spermatogenesis in some seminiferous tubules. We observed H19 imprinting errors in primary spermatocytes from one MAi patient and MEST imprinting errors in one MAi and two MAc patients. Additionally, H19 imprinting errors were observed in elongated spermatids/spermatozoa from one MAi patient. Nevertheless, no statistical differences were found for H19 and MEST global methylation levels (percentage of methylated and unmethylated CpGs, respectively) between patients with complete and incomplete MA and also between MA groups and a control group. These results provide further evidence that imprinting errors occur in spermatogenic cells from patients presenting impaired spermatogenesis, as we and others have previously described in ejaculated and testicular spermatozoa. As paternal imprinting errors can be transmitted to the embryo by the sperm cell, they can provide a possible explanation for poor embryo development and/or low pregnancy rates as correct expression of imprinted genes is crucial for embryo and placental development and function. Therefore, in cases with male factor infertility where unsuccessful in vitro fertilization (IVF) treatments are recurrent, analysis of imprinting marks in spermatozoa might be a useful diagnostic tool.